Core Insights - The article discusses the significant growth of China's innovative pharmaceuticals, projecting over $136 billion in cross-border transaction value by 2025, marking a shift from "single-point innovation" to "global value supply" [2] - The event aims to analyze the latest trends in cross-border licensing and M&A transactions, focusing on the ADC and oncology asset export logic, as well as the competitive landscape in the GLP-1 commercialization path [2] - The discussion will also cover the latest regulatory developments in the industry and the transformative potential of artificial intelligence in drug development, pipeline efficiency, and valuation frameworks [2] Event Details - The Bloomberg Pharmaceutical Market Insight Conference is scheduled for March 10, 2026, in Shanghai, featuring industry leaders and Bloomberg experts [2][3] - The agenda includes keynote speeches, panel discussions on future M&A technology routes, and interactive exchanges [3] Speakers - Notable speakers include executives from major companies such as China Biopharmaceutical Co., AbbVie China, and Bloomberg Industry Research, highlighting the expertise present at the event [4]

Group 1 - The core viewpoint of the article emphasizes the long-term growth potential of a specific optical module company, supported by its deep engagement in silicon photonics solutions and projected profit margin growth by 2026, indicating a potential revaluation of its valuation system [1] - The demand for upgraded products such as M9, quartz cloth, and high-end copper foil is expected to increase, with analysts strongly recommending the company's products as consumables in the production process, which are likely to benefit from the capacity release of downstream customers [1]